Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Biochim Biophys Acta Mol Basis Dis ; 1864(3): 668-675, 2018 Mar.
Article in English | MEDLINE | ID: mdl-29247835

ABSTRACT

Aspartylglucosaminuria (AGU) is a lysosomal storage disorder caused by mutations in the gene for aspartylglucosaminidase (AGA). This enzyme participates in glycoprotein degradation in lysosomes. AGU results in progressive mental retardation, and no curative therapy is currently available. We have here characterized the consequences of AGA gene mutations in a compound heterozygous patient who exhibits a missense mutation producing a Ser72Pro substitution in one allele, and a nonsense mutation Trp168X in the other. Ser72 is not a catalytic residue, but is required for the stabilization of the active site conformation. Thus, Ser72Pro exchange impairs the autocatalytic activation of the AGA precursor, and results in a considerable reduction of the enzyme activity and in altered AGA precursor processing. Betaine, which can partially rescue the AGA activity in AGU patients carrying certain missense mutations, turned out to be ineffective in the case of Ser72Pro substitution. The Trp168X nonsense allele results in complete lack of AGA polypeptide due to nonsense-mediated decay (NMD) of the mRNA. Amlexanox, which inhibits NMD and causes a translational read-through, facilitated the synthesis of a full-length, functional AGA protein from the nonsense allele. This could be demonstrated as presence of the AGA polypeptide and increased enzyme activity upon Amlexanox treatment. Furthermore, in the Ser72Pro/Trp168X expressing cells, Amlexanox induced a synergistic increase in AGA activity and polypeptide processing due to enhanced processing of the Ser72Pro polypeptide. Our data show for the first time that Amlexanox might provide a valid therapy for AGU.


Subject(s)
Aminopyridines/therapeutic use , Aspartylglucosaminuria/drug therapy , Aspartylglucosaminuria/genetics , Aspartylglucosylaminase/genetics , Codon, Nonsense , Amino Acid Substitution , Aminopyridines/pharmacology , Cells, Cultured , Child , Codon, Nonsense/drug effects , Female , HEK293 Cells , HeLa Cells , Humans , Lysosomal Storage Diseases/drug therapy , Lysosomal Storage Diseases/genetics , Mutation, Missense
2.
Sci Rep ; 6: 37583, 2016 11 23.
Article in English | MEDLINE | ID: mdl-27876883

ABSTRACT

Aspartylglucosaminuria (AGU) is a lysosomal storage disorder that is caused by genetic deficiency of the enzyme aspartylglucosaminidase (AGA) which is involved in glycoprotein degradation. AGU is a progressive disorder that results in severe mental retardation in early adulthood. No curative therapy is currently available for AGU. We have here characterized the consequences of a novel AGU mutation that results in Thr122Lys exchange in AGA, and compared this mutant form to one carrying the worldwide most common AGU mutation, AGU-Fin. We show that T122K mutated AGA is expressed in normal amounts and localized in lysosomes, but exhibits low AGA activity due to impaired processing of the precursor molecule into subunits. Coexpression of T122K with wildtype AGA results in processing of the precursor into subunits, implicating that the mutation causes a local misfolding that prevents the precursor from becoming processed. Similar data were obtained for the AGU-Fin mutant polypeptide. We have here also identified small chemical compounds that function as chemical or pharmacological chaperones for the mutant AGA. Treatment of patient fibroblasts with these compounds results in increased AGA activity and processing, implicating that these substances may be suitable for chaperone mediated therapy for AGU.


Subject(s)
Aspartylglucosaminuria/drug therapy , Molecular Chaperones/therapeutic use , Small Molecule Libraries/analysis , Small Molecule Libraries/therapeutic use , Amino Acid Sequence , Aspartylglucosaminuria/enzymology , Aspartylglucosylaminase/chemistry , Aspartylglucosylaminase/genetics , Base Sequence , Endoplasmic Reticulum/drug effects , Endoplasmic Reticulum/metabolism , Fibroblasts/drug effects , Fibroblasts/metabolism , Fibroblasts/pathology , Golgi Apparatus/drug effects , Golgi Apparatus/metabolism , HEK293 Cells , HeLa Cells , Humans , Lysosomes/drug effects , Lysosomes/metabolism , Male , Molecular Chaperones/pharmacology , Mutant Proteins/metabolism , Mutation/genetics , Small Molecule Libraries/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...